This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
by Zacks Equity Research
Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
by Kinjel Shah
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
by Zacks Equity Research
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Pfizer (PFE) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
by Zacks Equity Research
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Adobe, IBM, Sanofi, Enbridge and Itau Unibanco
by Zacks Equity Research
Adobe, IBM, Sanofi, Enbridge and Itau Unibanco are included in this Analyst Blog.
Top Stock Reports for Adobe, IBM & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), International Business Machines Corporation (IBM) and Sanofi (SNY).
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
by Zacks Equity Research
The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
by Zacks Equity Research
IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.
Top Research Reports for Meta Platforms, Broadcom & Verizon
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Broadcom Inc. (AVGO) and Verizon Communications Inc. (VZ).
Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint
by Zacks Equity Research
Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
by Kinjel Shah
Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why
by Zacks Equity Research
MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.
Here's Why Sanofi (SNY) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program
by Zacks Equity Research
Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
Top Analyst Reports for Alphabet, Comcast & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Comcast Corp. (CMCSA) and NextEra Energy, Inc. (NEE).
AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
by Zacks Equity Research
Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
by Zacks Equity Research
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.